New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2014
09:01 EDTINOFollow-up: Inovio 18.9M share Spot Secondary priced at $2.90
The deal range was raised to 18.9M shares from 13.4M shares. Piper Jaffray and Stifel acted as joint book running managers for the offering.
News For INO From The Last 14 Days
Check below for free stories on INO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2014
11:46 EDTINOOptions with decreasing implied volatility
Options with decreasing implied volatility: INO PBYI ANGI MLNX INFN TTS QLIK DECK SKX CRUS
July 28, 2014
11:18 EDTINOOptions with decreasing implied volatility
Subscribe for More Information
July 25, 2014
11:08 EDTINOOptions with decreasing implied volatility
Options with decreasing implied volatility: INO PBYI MLNX DECK INFN CMG QLIK LKX ANGI NFLX
July 24, 2014
11:15 EDTINOInovio upgraded to Buy from Hold at Aegis
Aegis upgraded Inovio to Buy following positive top-line data from the clinical trial of its lead human papillomavirus DNA-based vaccine, VGX-3100, in patients with high-grade cervical dysplasia. Price target raised to $19 from $10.
10:26 EDTINOOptions with decreasing implied volatility
Subscribe for More Information
July 23, 2014
16:47 EDTINOInovio files $175M mixed securities shelf
13:21 EDTINOInovio says ITT analysis achieved statistical significance in VGX-3100 trial
Subscribe for More Information
11:21 EDTINOOptions with decreasing implied volatility
Options with decreasing implied volatility: INO SHPG IRBT CMG LXK PSEC CROX ATHN VMW
11:08 EDTINOHigh option volume stocks
Subscribe for More Information
09:44 EDTINOInovio price target raised to $29 from $26 at Piper Jaffray
Subscribe for More Information
09:20 EDTINOInovio's VGX-3100 for cervical dysplasia shows positive Phase II results
Inovio Pharmaceuticals announced successful results from its randomized, double-blind, placebo-controlled phase II trial of VGX-3100 in women with biopsy-proven cervical intraepithelial neoplasia 2/3 associated with human papillomavirus types 16 or 18. Treatment with VGX-3100 resulted in histopathological regression of CIN2/3 to CIN1 or no disease, meeting the study's primary endpoint. The trial demonstrated clearance of HPV in conjunction with regression of cervical lesions. Robust T-cell activity was detected in subjects who received VGX-3100 compared to those who received placebo.
July 21, 2014
07:11 EDTINOInternational Society of DNA Vaccines to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use